Oncology News and Research

RSS
Researchers develop simple assay that reveals evolutionary relationships among various tumor sites within patient

Researchers develop simple assay that reveals evolutionary relationships among various tumor sites within patient

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

FDA and EC grant Orphan Drug Designation to Boehringer’s volasertib for acute myeloid leukemia

BRI scientists receive grant to study new approach to blocking metastatic breast cancer

BRI scientists receive grant to study new approach to blocking metastatic breast cancer

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Genmab/GSK receive FDA sBLA approval for Arzerra in combination with chlorambucil for treatment of CLL

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Research: Drugs used to treat lung, breast and pancreatic cancers promote drug-resistance, spur tumor growth

Twenty years data analysis shows patients treated with HIPEC may have improved survival rates

Twenty years data analysis shows patients treated with HIPEC may have improved survival rates

Three Johns Hopkins researchers awarded grants for work on potential treatments for diabetes

Three Johns Hopkins researchers awarded grants for work on potential treatments for diabetes

Viewpoints: Obamacare still has more challenges; GOP needs to help make law work; census change is not Obama's decision

Viewpoints: Obamacare still has more challenges; GOP needs to help make law work; census change is not Obama's decision

Men with chronic inflammation in non-cancerous prostate tissue may have nearly twice risk of prostate cancer

Men with chronic inflammation in non-cancerous prostate tissue may have nearly twice risk of prostate cancer

Skin docs prescribe costlier drugs after free samples

Skin docs prescribe costlier drugs after free samples

XBiotech announces results from Phase I/II oncology study

XBiotech announces results from Phase I/II oncology study

Study: Chronic inflammation associated with aggressive prostate cancer

Study: Chronic inflammation associated with aggressive prostate cancer

B1/Cdk1 protein which plays key role in cell division also boosts power of mitochondrial activity

B1/Cdk1 protein which plays key role in cell division also boosts power of mitochondrial activity

FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

FTC requests additional information relating to Actavis’ pending acquisition of Forest Laboratories

Actavis to purchase four currently marketed products from Akorn

Actavis to purchase four currently marketed products from Akorn

Researchers recommend early colorectal cancer screening guidelines for cervical cancer survivors

Researchers recommend early colorectal cancer screening guidelines for cervical cancer survivors

John Hopkins researchers create novel optical imaging equipment for use on SARRP research platform

John Hopkins researchers create novel optical imaging equipment for use on SARRP research platform

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

Cancer Research partners with AstraZeneca and Pfizer to create clinical trial for advanced lung cancer

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Boehringer grants volasertib 'orphan drug designation' for treatment of patients with AML

Researchers create clinical trial for patients with advanced lung cancer

Researchers create clinical trial for patients with advanced lung cancer

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.